Rights & Society
Meeting highlights from PRAC 7-10 April 2026
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) held its meeting from April 7-10, 2026. Key highlights included new safety information for healthcare professionals regarding Ontozry (cenobamate), with new requirements for liver monitoring due to severe liver injury reports. This ongoing work by PRAC ensures that the safety of medicines used by EU citizens is continuously monitored and updated based on the latest data. Citizens should be aware of these safety updates for prescribed medications.
EMA committee updates drug safety, emphasizing liver monitoring for Ontozry.